Study on the prediction scheme for poor prognosis of epithelial ovarian cancer-related immune-related LncRNAs based on TCGA and ImmPort

doi:10.3760/cma.j.cn441417-20250324-21014

Abstract

Abstract: Objective　To construct a prediction scheme for poor prognosis of epithelial ovarian cancer-related immune-related long non-coding ribonucleic acids (LncRNAs) based on the Cancer Genome Atlas (TCGA) database and the Immunology Database and Analysis Portal (ImmPort). Methods　LncRNAs data of epithelial ovarian cancer and adjacent normal tissues, as well as patients' clinical data, were downloaded from the TCGA database; differentially expressed immune-related LncRNAs were screened by combining immune related LncRNA data downloaded from ImmPort (as of May 31, 2024). Immune related LncRNAs independently associated with poor prognosis of epithelial ovarian cancer were screened using univariate and multivariate Cox regression analysis, and a risk scoring model was constructed. The predictive value of the risk scoring model was analyzed using the Kaplan-Meier survival analysis curve and receiver operating characteristic curve (ROC). Results　A total of 208 cases of epithelial ovarian cancer tissues and 104 cases of normal tissues adjacent to the cancer were downloaded from the TCGA database, and 128 differentially expressed immune-related LncRNAs were screened out. Univariate Cox regression analysis identified 11 immune-related LncRNAs that were associated with the prognosis of epithelial ovarian cancer (all P<0.05). Multivariate Cox regression analysis revealed 5 immune-related LncRNAs (MALAT1, LINC00958, AC011445.1, PRKAR1B-AS2, and SNHG17) that independently affected the prognosis of epithelial ovarian cancer (all P<0.05). Based on the results of multivariate Cox regression analysis, an immune-related LncRNA prognostic risk scoring model for epithelial ovarian cancer was constructed: the risk score = 0.592 × MALAT1 + 0.491 × LINC00958 + 0.413 × AC011445.1 + 0.641 × PRKAR1B-AS2 + 0.309 × SNHG17. The Kaplan-Meier survival analysis curve showed that the survival rate of the high-risk group (risk score ≥ median) was lower than that of the low-risk group (risk score < median) (Log-rank test: χ²=13.784, P<0.001). The ROC analysis showed that the area under the curve for predicting poor prognosis at 1 year, 3 years, and 5 years by the risk scoring model was 0.815 (95%CI: 0.754 - 0.867), 0.735 (95%CI: 0.667 - 0.796), and 0.691 (95%CI: 0.621 - 0.755), respectively. Conclusion　A risk scoring model based on above-mentioned 5 immune-related LncRNAs related to the prognosis of epithelial ovarian cancer can predict the prognosis and provide potential immunotherapy targets for epithelial ovarian cancer.

Key words: Epithelial ovarian cancer, Immune related genes, Long non-coding ribonucleic acids, Poor prognosis, Cancer Genome Atlas Database, Immunology Database and Analysis Portal

摘要： 目的　基于癌症基因组图谱（TCGA）数据库和免疫学数据库和分析门户（ImmPort）构建上皮性卵巢癌免疫相关长链非编码核糖核酸（LncRNAs）预后不良的预测方案。方法　从TCGA数据库中下载上皮性卵巢癌和癌旁正常组织LncRNAs数据和患者临床资料，并结合ImmPort下载的免疫相关LncRNAs数据筛选差异表达免疫相关LncRNAs（截止至2024年5月31日）。采用单因素和多因素Cox回归分析筛选与上皮性卵巢癌预后不良独立相关的免疫相关LncRNAs，构建风险评分模型，并通过Kaplan-Meier生存分析曲线、受试者操作特征曲线（ROC）分析风险评分模型的预测价值。结果　从TCGA数据库中共下载208例上皮性卵巢癌组织和104例癌旁正常组织的LncRNAs数据，筛选出128个差异表达免疫相关LncRNAs。单因素Cox回归分析共筛选出11个与上皮性卵巢癌预后相关的免疫相关LncRNAs（均P<0.05）；进一步进行多因素Cox回归分析，得出5个独立影响上皮性卵巢癌预后的免疫相关LncRNAs（MALAT1、LINC00958、AC011445.1、PRKAR1B-AS2、SNHG17）（均P<0.05）。基于多因素Cox回归分析结果构建上皮性卵巢癌免疫相关LncRNAs预后预测风险评分模型，风险评分=0.592×MALAT1 + 0.491×LINC00958 + 0.413×AC011445.1 + 0.641×PRKAR1B-AS2 + 0.309×SNHG17。Kaplan-Meier生存分析曲线显示，高风险组（风险评分≥中位数）与低风险组（风险评分<中位数）相比，生存率较低（Log-rank检验：χ²=13.784，P<0.001）。ROC分析显示，风险评分模型预测1年、3年、5年预后不良的曲线下面积分别为0.815（95%CI：0.754～0.867）、0.735（95%CI：0.667～0.796）、0.691（95%CI：0.621～0.755）。结论　基于上述5个上皮性卵巢癌预后相关的免疫相关LncRNAs构建的风险评分模型能够预测预后情况，也为上皮性卵巢癌提供潜在免疫治疗靶点。

Yan Xue, Liu Yuanyuan, Zhao Gang. Study on the prediction scheme for poor prognosis of epithelial ovarian cancer-related immune-related LncRNAs based on TCGA and ImmPort[J]. International Medicine and Health Guidance News, 2025, 31(21): 3592-3596.

颜雪刘媛媛赵刚. 基于TCGA和ImmPort的上皮性卵巢癌免疫相关LncRNAs预后不良的预测方案研究[J]. 国际医药卫生导报, 2025, 31(21): 3592-3596.

References

[1] 徐杰茹,陈磊,张敏,等. 1990-2019年中国卵巢癌发病与死亡趋势及其年龄-时期-队列模型分析[J]. 中国肿瘤,2022,31(4):276-283. DOI:10.11735/j.issn.1004-0242.2022.04.A005.
[2] Shao C, Guo H, Chen L, et al. Prognostic factors and clinic-pathologic characteristics of ovarian tumor with different histologic subtypes-a SEER database population study of 41,376 cases[J]. Transl Cancer Res, 2023, 12(8): 1937-1950. DOI:10.21037/tcr-23-58.
[3] Nowak M, Klink M. The role of tumor-associated macrophages in the progression and chemoresistance of ovarian cancer[J]. Cells, 2020, 9(5): 1299. DOI:10.3390/cells9051299.
[4] Rocconi RP, Monk BJ, Walter A, et al. Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer[J]. Gynecol Oncol, 2021, 161(3): 676-680. DOI:10.1016/j.ygyno.2021.03.009.
[5] Blanc-Durand F, Genestie C, Galende EY, et al. Distribution of novel immune-checkpoint targets in ovarian cancer tumor microenvironment: a dynamic landscape[J]. Gynecol Oncol, 2021, 160(1): 279-284. DOI:10.1016/j.ygyno.2020.09.045.
[6] Cibula D, Rob L, Mallmann P, et al. Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): a randomized, open-label, phase 2 trial[J]. Gynecol Oncol, 2021, 162(3): 652-660. DOI:10.1016/j.ygyno.2021.07.003.
[7] 戚新春,李阳,程卫. 甲状腺乳头状癌患者TCAB1、lncRNA DLEU2表达与临床病理参数及预后的相关性[J]. 国际医药卫生导报,2024,30(19):3302-3306. DOI:10.3760/cma.j.issn.1007-1245.2024.19.027.
[8] Zhang Z, Yan C, Li K, et al. Pan-cancer characterization of lncRNA modifiers of immune microenvironment reveals clinically distinct de novo tumor subtypes[J]. NPJ Genom Med, 2021, 6(1): 52. DOI:10.1038/s41525-021-00215-7.
[9] Saadi W, Fatmi A, Pallardó FV, et al. Long non-coding RNAs as epigenetic regulators of immune checkpoints in cancer immunity[J]. Cancers (Basel), 2022, 15(1): 184. DOI:10.3390/cancers15010184.
[10] Yeh CY, Aguirre K, Laveroni O, et al. Mapping spatial organization and genetic cell-state regulators to target immune evasion in ovarian cancer[J]. Nat Immunol, 2024, 25(10): 1943-1958. DOI:10.1038/s41590-024-01943-5.
[11] Palaia I, Tomao F, Sassu CM, et al. Immunotherapy for ovarian cancer: recent advances and combination therapeutic approaches[J]. Onco Targets Ther, 2020, 13: 6109-6129. DOI:10.2147/OTT.S205950.
[12] Eptaminitaki GC, Wolff N, Stellas D, et al. Long non-coding RNAs (lncRNAs) in response and resistance to cancer immunosurveillance and immunotherapy[J]. Cells, 2021, 10(12): 3313. DOI:10.3390/cells10123313.
[13] Oncul S, Amero P, Rodriguez-Aguayo C, et al. Long non-coding RNAs in ovarian cancer: expression profile and functional spectrum[J]. RNA Biol, 2020, 17(11): 1523-1534. DOI:10.1080/15476286.2019.1702283.
[14] Huang Y, Gui Z, Wu M, et al. Tumor-infiltrating B cell-related lncRNA crosstalk reveals clinical outcomes and tumor immune microenvironment in ovarian cancer based on single-cell and bulk RNA-sequencing[J]. Heliyon, 2024, 10(21): e39496. DOI:10.1016/j.heliyon.2024.e39496.
[15] Sun X, Li S, Lv X, et al. Immune-related long non-coding RNA constructs a prognostic signature of ovarian cancer[J]. Biol Proced Online, 2021, 23(1): 24. DOI:10.1186/s12575-021-00161-9.
[16] Mao TL, Fan MH, Dlamini N, et al. LncRNA MALAT1 facilitates ovarian cancer progression through promoting chemoresistance and invasiveness in the tumor microenvironment[J]. Int J Mol Sci, 2021, 22(19): 10201. DOI:10.3390/ijms221910201.
[17] Gordon MA, Babbs B, Cochrane DR, et al. The long non-coding RNA MALAT1 promotes ovarian cancer progression by regulating RBFOX2-mediated alternative splicing[J]. Mol Carcinog, 2019, 58(2): 196-205. DOI:10.1002/mc.22919.
[18] Xie M, Fu Q, Wang PP, et al. STAT1-induced upregulation lncRNA LINC00958 accelerates the epithelial ovarian cancer tumorigenesis by regulating Wnt/β-Catenin signaling[J]. Dis Markers, 2021, 2021: 1405045. DOI:10.1155/2021/1405045.
[19] Yan X, Yang Y, Guan H, et al. Exosomal LINC00958 maintains ovarian cancer cell stemness and induces M2 macrophage polarization via Hedgehog signaling pathway and GLI1 protein[J]. Int J Biol Macromol, 2024, 279(Pt 1): 135080. DOI:10.1016/j.ijbiomac.2024.135080.
[20] Peng Y, Wang H, Huang Q, et al. A prognostic model based on immune-related long noncoding RNAs for patients with epithelial ovarian cancer[J]. J Ovarian Res, 2022, 15(1): 8. DOI:10.1186/s13048-021-00930-w.
[21] Elsayed AM, Bayraktar E, Amero P, et al. PRKAR1B-AS2 long noncoding RNA promotes tumorigenesis, survival, and chemoresistance via the PI3K/AKT/mTOR pathway[J]. Int J Mol Sci, 2021, 22(4): 1882. DOI:10.3390/ijms22041882.
[22] Zheng ZJ, Liu Y, Wang HJ, et al. LncRNA SNHG17 promotes proliferation and invasion of ovarian cancer cells through up-regulating FOXA1[J]. Eur Rev Med Pharmacol Sci, 2020, 24(18): 9282-9289. DOI:10.26355/eurrev_202009_23010.
[23] Liang H, Geng S, Wang Y, et al. Tumour-derived exosome SNHG17 induced by oestrogen contributes to ovarian cancer progression via the CCL13-CCR2-M2 macrophage axis[J]. J Cell Mol Med, 2024, 28(9): e18315. DOI:10.1111/jcmm.18315.
[24] Li H, Liu ZY, Chen YC, et al. Identification and validation of an immune-related lncRNAs signature to predict the overall survival of ovarian cancer[J]. Front Oncol, 2022, 12: 999654. DOI:10.3389/fonc.2022.999654.
[25] Feng J, Yu Y, Yin W, et al. Development and verification of a 7-lncRNA prognostic model based on tumor immunity for patients with ovarian cancer[J]. J Ovarian Res, 2023, 16(1): 31. DOI:10.1186/s13048-023-01099-0.